BioAlliance says Doxorubicin Transdrug promising as liver cancer treatment

By Elaine Rigoli

Tampa, Fla., June 30 - BioAlliance Pharma said the preliminary results from its Doxorubicin Transdrug phase 1/ 2 clinical trial for primary liver cancer are very promising and represent an important step for the drug's development as the company prepares for the phase 2/ 3 trial slated for the third quarter.

These results are also positive because of their encouraging implications for the future application of the Transdrug nanotechnology platform, the company said in a news release.

During the trial, 20 patients with advanced liver cancer were treated with an injection of Doxorubicin Transdrug into the hepatic artery. The maximum tolerated dose in this study was 30 mg/m2, and this is the dose that will be used for the clinical development.

Doxorubicin Transdrug has been granted orphan-drug status by the EMEA in Europe and the Food and Drug Administration for the treatment of hepatocellular carcinoma, the most lethal form of liver cancer, and for which no approved treatment exists.

Transdrug is a treatment based on nanotechnology developed by BioAlliance Pharma. It allows intracellular drug targeting - a recognized medical benefit - to optimize drug efficacy and patient tolerance.

Doxorubicin Transdrug couples this technology with doxorubicin, a chemotherapeutic agent that is powerful and effective against many forms of cancer, the release said.

In the case of hepatocellular carcinoma, Doxorubicin Transdrug is injected into the liver via a catheter inserted in the hepatic artery.

BioAlliance Pharma is a Paris-based specialty pharmaceutical company focused on the development of therapeutics targeting drug resistance in cancer, HIV and severe and opportunistic infections.

© 2015 Prospect News.
All content on this website is protected by copyright law in the U.S. and elsewhere. For the use of the person downloading only.
Redistribution and copying are prohibited by law without written permission in advance from Prospect News.
Redistribution or copying includes e-mailing, printing multiple copies or any other form of reproduction.